Literature DB >> 26036507

Liver retransplantation in patients with acquired familial amyloid polyneuropathy: a Portuguese center experience.

H Vieira1, C Rodrigues2, L Pereira3, J Jesus2, C Bento3, C Seco3, F Pinto3, A Eufrásio3, S Calretas4, N Silva4, J Ferrão4, L Tomé4, A Barros4, D Diogo4, E Furtado4.   

Abstract

In 1995 Furtado et al performed the first domino transplantation using a donor liver with familial amyloid polyneuropathy (FAP), thereby increasing the pool of donors. Our experience showed that the onset of FAP symptoms occurs earlier in some patients. Patients with FAP acquired by transplantation are candidates for liver retransplantation to minimize the progression of symptoms. Liver retransplantation is considered to be a high-risk procedure and has lower survival compared with the first transplantation. We evaluated the risk of liver retransplantation in patients with acquired FAP. We did a retrospective analysis of these patients based on the records of perioperative data. From 1995 to 2004 we carried out 81 domino transplantations, of which 10 were submitted to liver retransplantation because of acquired FAP. The better outcomes in this group lead us to think that the liver retransplantation in patients with acquired FAP is not associated with the same risks of liver retransplantation in candidates with graft failure.
Copyright © 2015 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2015        PMID: 26036507     DOI: 10.1016/j.transproceed.2015.04.003

Source DB:  PubMed          Journal:  Transplant Proc        ISSN: 0041-1345            Impact factor:   1.066


  2 in total

Review 1.  Iatrogenic amyloid polyneuropathy after domino liver transplantation.

Authors:  Diana Mnatsakanova; Saša A Živković
Journal:  World J Hepatol       Date:  2017-01-28

2.  Treatment With Diflunisal in Domino Liver Transplant Recipients With Acquired Amyloid Neuropathy.

Authors:  Velina Nedkova-Hristova; Carmen Baliellas; José González-Costello; Laura Lladó; Emma González-Vilatarsana; Valentina Vélez-Santamaría; Carlos Casasnovas
Journal:  Transpl Int       Date:  2022-04-13       Impact factor: 3.842

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.